Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor has demonstrated efficacy in tumors harboring the EGFR T790M resistance mutation. Inevitably, resistance to third-generation inhibitors results in disease progression, with the EGFR C797S mutation being one of several resistance pathways identified to date. On the basis of preclinical data, we report what is the first known case of a patient harboring the T790M and C797S mutations in trans treated with combination gefitinib and osimertinib.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Thorac Oncol

Title: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Publisher: Elsevier BV

ISSN (Electronic): 1556-1380

ISSN (Print): 1556-0864

Publication date (Electronic): Nov 2017

Volume: 12

Issue: 11

Affiliations

[1 ] Cancer Immunobiology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.

[2 ] School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia; Translational Genomics and Epigenomics Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia; Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.

[3 ] Translational Genomics and Epigenomics Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.

[4 ] Cancer Immunobiology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia; Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Victoria, Australia.

[5 ] Cancer Immunobiology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia; Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Victoria, Australia. Electronic address: Tom.John@onjcri.org.au.

Article

Publisher Item ID: S1556-0864(17)30681-0

DOI: 10.1016/j.jtho.2017.08.006

PubMed ID: 28843359

SO-VID: 6bf23e9d-228d-41eb-9072-6daab22425aa

History

Keywords: Osimertinib,Non–small cell lung cancer,C797S mutation,EGFR mutation,Gefitinib

Data availability:

Keywords: Osimertinib, Non–small cell lung cancer, C797S mutation, EGFR mutation, Gefitinib

Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.

Read this article at

Abstract

Related collections

Cancer Immunotherapy

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 593

Cited by 69